Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation

Cytometry

Volumn 27, Issue 1, 1997, Pages 43-53

  Smith, Paul J ^a,d   Desnoyers, Rodwige ^a,c   Blunt, Nicola ^a,d   Giles, Yvonne ^b   Patterson, Laurence H ^b   Watson, James V ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

anthraquinones; anticancer drugs; confocal microscopy; DNA intercalation; DNA topoisomerase II inhibitors; flow cytometry; hypoxia; N oxide; prodrugs

Indexed keywords

ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; MITOXANTRONE; PRODRUG;

ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DNA INTERCALATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; KRYPTON LASER; PRIORITY JOURNAL; TUMOR CELL;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; CELL LINE, TRANSFORMED; DNA; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; KRYPTON; LASERS; MICROSCOPY, CONFOCAL; MITOXANTRONE; PRODRUGS;

EID: 0031019255     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19970101)27:1<43::AID-CYTO6>3.0.CO;2-M     Document Type: Article

References (35)

1. Bell DH: Characterization of the fluorescence of the antitumour agent mitoxantrone. Biochim Biophys Acta 949: 132-137, 1988.
2. Bowden GT, Roberts R, Alberts DS, Peng Y-M, Garcia D: Comparative molecular pharmacology in leukaemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene. Cancer Res 45: 4915-4920, 1985.
3. Brown JM, Giaccia AJ: Tumour hypoxia: the picture has changed in the 1990s. Int J Radiat Biol 65: 95-102, 1994.
4. Chen K-X, Gresh N, Pullman, B: A theoretical investigation on the sequence-selective binding of mitoxantrone to double stranded DNA. Nucleic Acids Res 14: 3799-3803, 1986.
5. Cheng CC, Zee-Cheng RK-Y: The design, synthesis, and development of a new class of potent antineoplastic anthraquinones. In: Progress in Medicinal Chemistry, Ellis, GP, West, GB (eds). Vol 20 Elsevier Science Publ, 1983, pp 83-115.
6. Cheng CC, Zbinden G, Zee-Cheng RK-Y: Comparison of antineoplastic activity of aminoethylaminoanthraquinones and anthracycline antibiotics. J Pharm Sci 68: 393-396, 1979.
7. Cress AE, Roberts, RA, Bowden, GT, Dalton, WS: Modification of keratin by the chemotherapeutic drug mitoxantrone. Biochem Pharmacol 37: 3043-3046, 1988.
8. Dalton WS, Cress AE, Alberts DS, Trent JM: Cytogenetic and phenotypic analysis of a human colon carcinoma cell line resistant to mitoxantrone. Cancer Res 48: 1882-1888, 1988.
9. Denny WA, Wakelin LPG: Kinetics of binding of mitoxantrone, ametantrone, and analogues to DNA: relationship with binding mode and anti-tumor activity. Anti-Cancer Drug Design 5: 189-200, 1990.
10. Egorin MJ, Hildebrand RC, Cimino EF, Bachur NR: (1974) Cytofluorescence localisation of Adriamycin and daunorubicin. Cancer Res 34: 2243.
11. Epstein RJ, Smith PJ: Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase-II interactive intercalative drugs. Cancer Res 48: 297-303, 1988.
12. Fox ME, Smith PJ: Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumour DNA intercalators mAMSA and mitoxantrone. Cancer Res 50: 5813-5818, 1990.
13. Fox ME, Smith PJ: Subcellular localisation of the antitumour drug mitoxantrone and the induction of DNA damage in resistant and sensitive human colon carcinoma cells. Cancer Chemother Pharmac 35: 403-410, 1995.
14. Gervasoni Jr JE, Fields SZ, Krishna S, Baker MA, Rosado M, Thurasamy K, Hindenburg AA, Taub RN: Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res 51: 4955-4963, 1991.
15. Ho AD, Seither E, Ma DDF, Prentice HG: Mitozantrone-induced toxicity and DNA strand breaks in leukaemic cells. Br J Haematology 65: 51-55, 1987.
16. Islam SA, Neidle S, Gandecha BM, Partridge M, Patterson LH, Brown JR: Comparative computer graphics and solution studies of the DNA interaction of substituted anthraquinones base on doxorubicin and mitoxantrone. J Med Chem 28: 857-864, 1985.
17. Krishan A, Ganapathi R: Laser flow studies on the intracellular fluorescence of anthracyclines. Cancer Res 40: 3895-3900, 1980.
18. Liu LF: DNA topoisomerase poisons as anti-tumour drugs. Annu Rev Biochem 58: 351-375, 1989.
19. 2. J Biol Struct Dyn 2: 1097-1106, 1985.
20. Lown JW, Morgan AR, Yen S-F, Wang YH, Wilson WD: Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochem 24: 4028-4035, 1985.
21. Murdock KC, Child RG, Fabio PF, Angier RB, Wallace RE, Durr FE, Citarella RV: Antitumor agents 1 1,4-bis[(aminoalkyl)amino]-9,10-anthracenediones. J Med Chem 22: 1024-1030, 1979.
22. Overgaard J: Sensitization of hypoxic tumour cells - clinical experience. Int JRadiat Biol 56: 801-811, 1989.
23. 123I-iodazomycin arabinoside: preliminary report of a clinical study. Brit J Cancer 65: 90-95, 1992.
24. Patterson LH, Maine JE, Cairns DC, Craven MR, Bennett N, Fisher, GR, Ruparelia K, Giles, Y: N-oxides of DNA affinic agents as bioreductively activated prodrugs. Proc Am Soc Cancer Res 33: 2571, 1992.
25. Patterson LH: Anthraquinone anticancer compounds with (disubstituted amino-N-oxide)alkylamino substituent. UK Patent GB 2 237 283, 1989.
26. Patterson, LH: Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer and Metastasis Reviews 12: 119-134, 1993.
27. Roberts, RA, Cress, AE, Dalton, WS: Persistent intracellular binding of mitoxantrone in a human colon carcinoma cell line. Biochem Pharmacol 38: 4283-4290, 1989.
28. Shenkenberg, TD, Von Hoff, DD: Mitoxantrone: a new anti-cancer drug with significant clinical activity. Ann Intern Med 105: 67-81, 1986.
29. Smith, PJ, Makinson, TA: Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line. Cancer Res 49: 1118-1124, 1989.
30. Smith PJ, Morgan SA, Fox ME, Watson JV: Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. Biochem Pharmac 40: 2069-2078, 1990.
31. Smith PJ, Sykes HR, Fox ME, Furlong IJ: Subcellular distribution of the anticancer drug mitoxantrone in human and drug-resistant murine cells analyzed by flow cytometry and confocal microscopy and its relationship to the induction of DNA damage. Cancer Res 51: 1-9, 1992.
32. Wallace RE, Lindh D and Durr FE: Development of resistance and characteristics of a human colon carcinoma subline resistant to mitoxantrone in vitro. Cancer Invest 5: 417-428, 1987.
33. Wang JC: Recent studies of DNA topoisomerases. Biochim Biophys Acta 909: 1-9, 1987.
34. White JG, Amos WB, Fordham M: Evaluation of confocal versus conventional imaging of biological structures by fluorescence light microscopy. J Cell Biol 105: 41-48, 1987.
35. Yanowich S, Taub RN: Differences in daunomycin retention in sensitive and resistant P388 leukemic cells as determined by digitized video fluorescence microscopy. Cancer Res 41: 4167-4171, 1983.